← Back to patent-cliff list
Bendamustine (Exinda)
Tier C — Watch / tradeBendamustine (Exinda)
Exinda Therapeutics LL
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DNA
Indications (approved)：Chronic lymphocytic leukaemia
Regional status
US
Phase III
2024-01-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Bendamustine (Exinda)?
Approved indications include: Chronic lymphocytic leukaemia.
When does the Bendamustine (Exinda) patent expire?
No public expiry year is available for Bendamustine (Exinda) yet; this page updates once verified.
How do I get a quote for Bendamustine (Exinda) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02